Hypoglycemic composition containing pioglitazone and preparation method of hypolipidemic composition

A technology of pioglitazone and a composition is applied in the field of hypoglycemic composition containing pioglitazone and its preparation, which can solve the problems of rising incidence of diabetes, insignificant treatment effect, limited clinical application, etc., so as to improve glucose balance disorder and prevent heart disease. Vascular disease, effect on reducing hypoglycemic response

Inactive Publication Date: 2016-11-16
卢连伟
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, Western medicine is mainly used for the treatment of type 2 diabetes, but the most prominent adverse reaction of these medicines is hypoglycemia, which may induce weight gain, which limits its clinical application and causes side effects on kidney, liver, spleen and other organs. There are also many disadvantages in the current traditional C

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hypoglycemic composition containing pioglitazone and preparation method of hypolipidemic composition
  • Hypoglycemic composition containing pioglitazone and preparation method of hypolipidemic composition
  • Hypoglycemic composition containing pioglitazone and preparation method of hypolipidemic composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] A hypoglycemic composition containing pioglitazone, said composition comprising by weight components: 0.05 parts of pioglitazone, 0.5 parts of acetazolamide, 1.2 parts of vitamin A, 0.6 parts of folic acid, 0.5 parts of benzoic acid, 0.3 parts of taurine 0.8 parts of acesulfame honey, 0.2 parts of lentinan, 0.7 parts of vitamin B12, 0.4 parts of proline, 0.6 parts of calcium citrate, 0.2 parts of xylitol, 0.05 parts of complex enzymes, 0.9 parts of magnesium stearate, carboxymethyl 2 parts of sodium starch glycolate, 5 parts of binder.

[0022] Wherein, the binder is highly substituted hydroxypropyl cellulose, and using high substituted hydroxypropyl cellulose as the binder can not only improve the fluidity and compressibility of the particles of the prepared composition. Great improvement, and no significant impact on other indicators of the product.

[0023] A preparation method of a hypoglycemic composition containing pioglitazone is:

[0024] (1) Pioglitazone, ace...

Embodiment 2

[0030] A hypoglycemic composition containing pioglitazone, said composition comprising by weight components: 0.10 parts of pioglitazone, 1.65 parts of acetazolamide, 2.3 parts of vitamin A, 1.3 parts of folic acid, 1.0 parts of benzoic acid, 0.6 parts of taurine 1.1 parts of acesulfame honey, 0.4 parts of lentinan, 0.85 parts of vitamin B12, 0.6 parts of proline, 0.9 parts of calcium citrate, 0.5 parts of xylitol, 0.065 parts of compound enzyme, 1.7 parts of magnesium stearate, carboxymethyl 4 parts of sodium starch glycolate, 22.5 parts of binder.

[0031] Wherein, the binder is highly substituted hydroxypropyl cellulose, and using high substituted hydroxypropyl cellulose as the binder can not only improve the fluidity and compressibility of the particles of the prepared composition. Great improvement, and no significant impact on other indicators of the product.

[0032] A preparation method of a hypoglycemic composition containing pioglitazone is:

[0033] (1) Pioglitazon...

Embodiment 3

[0039] A hypoglycemic composition containing pioglitazone, said composition comprising by weight components: 0.15 parts of pioglitazone, 2.8 parts of acetazolamide, 3.4 parts of vitamin A, 2.0 parts of folic acid, 1.5 parts of benzoic acid, 0.9 parts of taurine 1.4 parts of acesulfame honey, 0.6 parts of lentinan, 1.0 parts of vitamin B12, 0.8 parts of proline, 1.2 parts of calcium citrate, 0.8 parts of xylitol, 0.08 parts of compound enzyme, 2.5 parts of magnesium stearate, carboxymethyl 6 parts of sodium starch glycolate, 40 parts of binder.

[0040] Wherein, the binder is highly substituted hydroxypropyl cellulose, and using high substituted hydroxypropyl cellulose as the binder can not only improve the fluidity and compressibility of the particles of the prepared composition. Great improvement, and no significant impact on other indicators of the product.

[0041] A preparation method of a hypoglycemic composition containing pioglitazone is:

[0042] (1) Pioglitazone, ac...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a hypoglycemic composition containing pioglitazone and a preparation method of the hypoglycemic composition. The composition consists of the following components in parts by weight: 0.05-0.15 parts of pioglitazone, 0.5-2.8 parts of acetazolamide, 1.2-3.4 parts of vitamin A, 0.4-0.8 parts of arabinose, 0.6-2.0 parts of folic acid, 0.5-1.5 parts of benzoic acid, 0.3-0.9 parts of taurine, 0.8-1.4 parts of acesulfame, 0.2-0.6 parts of lentinan , 0.7-1.0 part of vitamin B12, 0.4-0.8 parts of proline, 0.6-1.2 parts of calcium citrate, 0.2-0.8 parts of xylitol, 0.05-0.08 parts of complex enzyme, 0.9-2.5 parts of magnesium stearate, 2-6 parts of carboxymethyl starch and 5-40 parts of a binding agent. The hypoglycemic composition disclosed by the invention, which is added with adjuvant materials, can be prepared into tablets or capsules by virtue of a conventional process; the hypoglycemic composition is simple in using method; and upon clinical verification, the hypoglycemic composition is good in hypoglycemic and diuretic effects.

Description

technical field [0001] The invention relates to the technical field of diabetes medication, in particular to a hypoglycemic composition containing pioglitazone and a preparation method thereof. Background technique [0002] With the improvement of people's living standards in our country, the change of life behavior and the increase of social aging, the prevalence of diabetes is showing a rapid upward trend. Diabetes is one of the most common chronic diseases, and the incidence of type 2 diabetes is relatively high. Many, type 2 diabetes means that the ability to produce insulin in the patient's body is not completely lost. Some patients even produce too much insulin in the body, but the effect of insulin is poor. Oral medications stimulate the secretion of insulin in the body. However, some patients still need to use insulin therapy in the later stage. The clinical manifestations of diabetes are hyperglycemia. The common symptoms are polydipsia, polyuria, polyphagia, and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/47A61P3/10A61K31/715A61K31/714A61K31/519A61K31/4439A61K31/433A61K31/401A61K31/194A61K31/185A61K31/07A61K31/047
Inventor 卢连伟
Owner 卢连伟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap